# US 2009/0269352 A1 · Antitumor agent comprising sulfonamide-containing heterocyclic compound combined with an angiogenesis inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0269352 A1
- Document ID: US20090269352A1
- Status: Published application
- Kind: A1
- Application number: 12/498,303
- Filed: 2009-07-06
- Published: 2009-10-29
- Earliest claimed: 2002-03-05
- Inventors: Toshiaki WAKABAYASHI; Naoto Ono; Taro Semba; Toru Haneda
- Web page: https://patentgrep.com/patent/US20090269352A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/502: ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a composition and a kit for treating tumors, which permits a sulfonamide-containing heterocyclic compound to exhibit its angiogenesis inhibitory activity and antitumor activity more effectively. According to the present invention, the sulfonamide-containing heterocyclic compound can be used in treating cancers more effectively by combination with a VEGF inhibitor/FGF inhibitor.

## Claims

### Claim 1

An antitumor agent comprising a sulfonamide-containing heterocyclic compound represented by the formula (II), a pharmacologically acceptable salt thereof or a hydrate of them combined with an angiogenesis inhibitor

### Claim 2 (depends on 1)

The antitumor agent according to claim 1, wherein the angiogenesis inhibitor is a VEGF receptor kinase inhibitor.

### Claim 3 (depends on 2)

The antitumor agent according to claim 2, wherein the VEGF receptor kinase inhibitor is ZD4190, ZD6474, SU5416, SU6668, SU11248, CEP-7055, CP-547632, KRN633 or PTK787.

### Claim 4 (depends on 2)

The antitumor agent according to claim 2, wherein the VEGF receptor kinase inhibitor is represented by the formula (III):
wherein R1 represents a hydrogen atom, methyl group, ethyl group, n-propyl group or cyclopropyl group, and R2 represents a group represented by the formula —NH2 or a group represented by the formula —NHOMe.

### Claim 5 (depends on 2)

The antitumor agent according to claim 2, wherein the VEGF receptor kinase inhibitor is represented by the formula (III):
wherein R1 represents ethyl or cyclopropyl group, and R2 represents a group represented by the formula —NH2 or a group represented by the formula —NHOMe.

### Claim 6 (depends on 1)

The antitumor agent according to claim 1, wherein the angiogenesis inhibitor is a VEGF antibody.

### Claim 7 (depends on 1)

The antitumor agent according to claim 1, wherein the angiogenesis inhibitor is an FGF receptor kinase inhibitor.

### Claim 8 (depends on 7)

The antitumor agent according to claim 7, wherein the FGF receptor kinase inhibitor is PD166866 or PD173074.

### Claim 9 (depends on 1)

The antitumor agent according to claim 1, wherein the angiogenesis inhibitor is an FGF antibody.
